This study aimed to evaluate the clinical validity of genetic variants that have been associated with AD by exploring the aggregate effect of associated SNPs on risk prediction for AD. Prior studies on the clinical use of genetic information in predicting risk for other complex disorders have investigated the effect of genetic sum scores in risk assessment and shown significant, but small, AUCs. In our study, genetic sum scores were created based on results from two different sources: SNPs that were associated with AD in family-based candidate gene studies and SNPs from GWAS analyses that met varying p-value thresholds. ROC curve analysis was used to assess the ability of the sum scores to classify cases and controls for AD.
